Renal Anemia | Access and Reimbursement | US | 2016

launch Related Market Assessment Reports

• Biomarkers In Oncology – Access & Reimbursement – Detailed, Expanded Analysis: Biomarkers In Oncology – Non-Small-Cell Lung Cancer, Breast Cancer, And Colorectal Cancer (US)

  September 2023

  Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…

• Nonalcoholic Steatohepatitis – Current Treatment – Detailed, Expanded Analysis: Current Treatment: Physician Insights (US)

  September 2023

• Systemic Lupus Erythematosus – Landscape & Forecast – Disease Landscape & Forecast

  September 2023

  Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…

• Glaucoma – Unmet Need – Detailed, Expanded Analysis (US/EU)

  September 2023

  Glaucoma is a progressive disease of the optic nerve caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in the United States and Europe. The majority of…

• Dry And Wet Age-Related Macular Degeneration – Unmet Need – Detailed, Expanded Analysis: Geographic Atrophy (US/EU)

  September 2023

  Geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), is a leading cause of visual impairment and blindness in the United States and Europe. Degradation of cells…